Drug intelligence / Profile preview

CNP-1001 (SiNON Nano Sciences)

Development stage: Preclinical
Lead developer: SiNON Nano Sciences
Modality: Nanoparticles → Drug Delivery Systems

Overview

CNP-1001 is a carbon nanoparticle (CNP) drug delivery platform developed by SiNON Nano Sciences. The platform is specifically designed to enable or enhance the delivery of therapeutic cargos across the blood-brain barrier (BBB), a major challenge in the treatment of central nervous system (CNS) disorders. By utilizing carbon nanoparticles as carriers, CNP-1001 aims to improve the bioavailability and targeted delivery of drugs to the brain, potentially increasing efficacy and reducing systemic side effects for various neurological conditions. The program is currently in the preclinical stage of development.

Other names: CNP

Beyond the preview

Go deeper on CNP-1001 (SiNON Nano Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNP-1001 (SiNON Nano Sciences).

Explore the full profile